AKR1C4 Antibody (N-term)
Affinity Purified Rabbit Polyclonal Antibody (Pab)
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| WB, E |
---|---|
Primary Accession | P17516 |
Other Accession | NP_001809.2 |
Reactivity | Human |
Host | Rabbit |
Clonality | Polyclonal |
Isotype | Rabbit IgG |
Calculated MW | 37067 Da |
Antigen Region | 11-39 aa |
Gene ID | 1109 |
---|---|
Other Names | Aldo-keto reductase family 1 member C4, 111-, 3-alpha-HSD1, 3-alpha-hydroxysteroid dehydrogenase type I, Chlordecone reductase, CDR, Dihydrodiol dehydrogenase 4, DD-4, DD4, HAKRA, AKR1C4, CHDR |
Target/Specificity | This AKR1C4 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 11-39 amino acids from the N-terminal region of human AKR1C4. |
Dilution | WB~~1:1000 |
Format | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. |
Storage | Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
Precautions | AKR1C4 Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | AKR1C4 |
---|---|
Synonyms | CHDR |
Function | Cytosolic aldo-keto reductase that catalyzes the NADH and NADPH-dependent reduction of ketosteroids to hydroxysteroids. Liver specific enzyme that acts as an NAD(P)(H)-dependent 3-, 17- and 20- ketosteroid reductase on the steroid nucleus and side chain (PubMed:10634139, PubMed:10998348, PubMed:11158055, PubMed:14672942, PubMed:1530633, PubMed:19218247, PubMed:7650035). Displays the ability to catalyze both oxidation and reduction in vitro, but most probably acts as a reductase in vivo since the oxidase activity measured in vitro is inhibited by physiological concentration of NADPH (PubMed:14672942). Acts preferentially as a 3-alpha-hydroxysteroid dehydrogenase (HSD) with a subsidiary 3-beta-HSD activity (PubMed:14672942). Catalyzes efficiently the transformation of the potent androgen 5-alpha-dihydrotestosterone (5alpha-DHT or 17beta- hydroxy-5alpha-androstan-3-one) into the less active form, 5-alpha- androstan-3-alpha,17-beta-diol (3-alpha-diol) (PubMed:10998348, PubMed:11158055, PubMed:14672942). Catalyzes the reduction of estrone into 17beta-estradiol but with low efficiency (PubMed:14672942). Metabolizes a broad spectrum of natural and synthetic therapeutic steroid and plays an important role in metabolism of androgens, estrogens, progestereone and conjugated steroids (PubMed:10998348, PubMed:14672942, PubMed:19218247). Catalyzes the biotransformation of the pesticide chlordecone (kepone) to its corresponding alcohol leading to increased biliary excretion of the pesticide and concomitant reduction of its neurotoxicity since bile is the major excretory route (PubMed:2427522). |
Cellular Location | Cytoplasm, cytosol {ECO:0000250|UniProtKB:Q04828} |
Tissue Location | Liver specific. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
AKR1C4 is a member of the aldo/keto reductase superfamily, which consists of more than 40 known enzymes and proteins. These enzymes catalyze the conversion of aldehydes and ketones to their corresponding alcohols by utilizing NADH and/or NADPH as cofactors. The enzymes display overlapping but distinct substrate specificity. This enzyme catalyzes the bioreduction of chlordecone, a toxic organochlorine pesticide, to chlordecone alcohol in liver. This gene shares high sequence identity with three other gene members and is clustered with those three genes at chromosome 10p15-p14.
References
Joslyn, G., et al. Alcohol. Clin. Exp. Res. 34(5):800-812(2010)
Guey, L.T., et al. Eur. Urol. 57(2):283-292(2010)
Li, J., et al. Breast Cancer Res. 12 (2), R19 (2010) :
Hosgood, H.D. III, et al. Respir Med 103(12):1866-1870(2009)
Shen, M., et al. Environ. Mol. Mutagen. 50(4):285-290(2009)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.